The Find It Early Act requires group and individual health plans, Medicare (including Medicare Advantage), Medicaid, TRICARE, and the Department of Veterans Affairs to cover additional breast screening and diagnostic imaging without cost-sharing for people identified as at increased risk of breast cancer or who have heterogeneously or extremely dense breasts. Covered modalities explicitly include 2D/3D mammography, breast ultrasound, breast MRI, molecular breast imaging, and other technologies as determined by applicable clinical guidance.
The bill uses the American College of Radiology (ACR) Appropriateness Criteria, the National Comprehensive Cancer Network (NCCN) guidelines, and the ACR’s BI-RADS density categories to define eligibility and lets treating clinicians determine need for others based on those standards. It takes effect for plan years beginning January 1, 2026, harmonizing benefit rules across public and private payers while raising implementation and cost-management issues for payers, states, and federal programs.
At a Glance
What It Does
Amends the Public Health Service Act, the Social Security Act, Title 10 (military health), and Title 38 (VA) to require no-cost-sharing coverage for unlimited-frequency breast screening and diagnostic imaging for people at higher risk or with dense breasts, and for others when a clinician determines imaging is necessary under ACR/NCCN guidance. It also updates grandfathered plan rules and Medicaid benchmark requirements.
Who It Affects
Applies to employer-sponsored group plans and individual market policies subject to ACA preventive services rules, Medicare fee-for-service and Advantage, Medicaid state plans and benchmark coverage, TRICARE beneficiaries, and VA-covered veterans. Health systems, radiology providers, and state Medicaid agencies will need to adjust policies and billing workflows.
Why It Matters
Creates a single, cross-program standard that eliminates cost barriers for higher-risk populations and those with dense breasts—groups where standard mammography is less sensitive—potentially increasing early detection. At the same time it shifts utilization and fiscal pressure onto payers and public programs and requires operational changes (eligibility criteria, coding, prior authorization practices).
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill inserts a new, mandatory preventive benefit into the ACA preventive-services framework so that private group and individual plans must cover additional breast imaging without patient cost-sharing when clinical criteria indicate elevated risk or dense breast tissue. It does this by revising section 2713 of the Public Health Service Act to add a subparagraph that lists covered modalities and ties eligibility to the most recent ACR Appropriateness Criteria or NCCN guidelines and BI-RADS density definitions.
That change also applies to plans that were previously 'grandfathered' under the ACA, narrowing prior exceptions.
For Medicare, the bill amends the Social Security Act to treat the specified breast imaging as covered items beginning January 1, 2026, for beneficiaries who meet the ACR/NCCN or clinician-determined criteria. It explicitly extends the no-cost-sharing rule into Medicare Advantage by requiring those additional imaging services be treated as part of covered preventive services under Advantage benefit rules.
For Medicaid, the bill does two things: first, it requires State Medicaid plans to furnish the screening and diagnostic imaging without cost-sharing for eligible enrollees (and prohibits alternative cost-sharing arrangements from excluding these services); second, it bars states from using benchmark or benchmark-equivalent coverage to omit the benefit.The Department of Defense/TRICARE and the Department of Veterans Affairs are brought into parity with civilian programs. Title 10 is amended so TRICARE covers the listed imaging modalities for eligible uniformed service members and beneficiaries and prohibits cost-sharing under TRICARE Prime and Select for those services.
The VA receives a new statutory section requiring the Veterans Health Administration to furnish the same imaging without copayments to eligible veterans, regardless of enrollment status in annual VA patient enrollment systems.Operationally, the bill delegates clinical eligibility to 'most recent applicable' ACR Appropriateness Criteria and NCCN guidance and to clinician judgment where appropriate. That delegation simplifies statutory micro-definitions but creates an implementation load: payers must update coverage policies, claims systems and provider notices to reflect modality lists, clinician-determined exceptions, BI-RADS density triggers, and the ban on frequency limits.
States that rely on legislative action to change Medicaid plans get a one-year implementation window tied to their legislative calendar.
The Five Things You Need to Know
The bill removes frequency limits: eligible individuals may receive screening and diagnostic breast imaging 'with no limitation applied on frequency' for the listed modalities.
Eligibility hinges on the 'most recent applicable' ACR Appropriateness Criteria or NCCN guidelines and BI-RADS definitions for dense breasts, with clinician judgment authorized to expand coverage based on age, race, ethnicity, or personal/family history.
It requires no cost-sharing for the benefit across private group and individual plans subject to ACA rules, Medicare fee-for-service, Medicare Advantage, Medicaid (including benchmark coverage), TRICARE, and VA benefits.
The statutory effective date is January 1, 2026 for most provisions; states that need changes to state law for Medicaid have an implementation delay tied to the next legislative session.
Grandfathered employer plans are explicitly brought into scope by amending ACA grandfathering rules so newly added imaging coverage cannot be excluded by a grandfathered status.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Adds unlimited-frequency breast imaging as an ACA preventive benefit
This provision revises the preventive services mandate to add a new subparagraph requiring group health plans and individual market policies to cover screening and diagnostic breast imaging for people at increased risk or with heterogeneously/extremely dense breasts, and for others when a clinician determines imaging is medically necessary under ACR/NCCN guidance. Practically, insurers must update plan documents, member communications, and claims edits to remove copays, coinsurance and frequency caps for the listed modalities for eligible members.
Makes additional breast imaging covered for Medicare and Advantage with no cost-sharing
The bill adds a clause to Medicare’s benefit definition making the imaging services covered beginning January 1, 2026, for beneficiaries who meet the criteria. It also instructs the Secretary to treat these services as covered under Medicare Advantage, ensuring MA plans cannot impose cost-sharing for them. Administratively, CMS must issue guidance and adjust coverage manuals, MBI edits, and MA risk adjustment/quality reporting treatment.
Requires Medicaid coverage and prohibits cost-sharing and benchmark carve-outs
Medicaid eligibility is expanded to include these services for qualifying enrollees, and the bill amends cost-sharing rules (sections 1916 and 1916A) so states cannot collect copayments for them. It also adds a non‑waivable benchmark requirement: states may not enroll beneficiaries in benchmark or benchmark‑equivalent plans unless those plans include the benefit. States that need new legislation get a defined implementation delay tied to their next regular session.
TRICARE coverage and elimination of copays for eligible beneficiaries
This section adds the imaging benefit to the TRICARE statutory benefit package and explicitly bans cost-sharing for eligible beneficiaries under TRICARE Prime, Select, and contracted plans. The Department of Defense will need to update TRICARE policy handbooks, provider reimbursement rules, and beneficiary cost-share schedules to comply.
VA must furnish imaging and waive copays for eligible veterans
The bill creates a new VA statutory section requiring the Veterans Health Administration to provide the listed screening and diagnostic imaging to eligible veterans without copayments, regardless of enrollment in the VA’s annual patient enrollment system. The VA must incorporate the ACR/NCCN criteria and BI-RADS density definitions into clinical eligibility guidance and update scheduling, outreach, and copay systems to eliminate charges for these services.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Individuals at increased risk for breast cancer (including those with genetic, personal, or family histories) — they gain removal of cost barriers to higher-sensitivity imaging and more frequent surveillance.
- People with heterogeneously or extremely dense breasts — legislation treats density as a trigger for additional imaging coverage, addressing known mammography sensitivity gaps.
- Medicare, TRICARE, and VA beneficiaries who meet the clinical criteria — these populations receive parity with private plan preventive benefits and no copays for the listed services.
- Clinicians and radiology providers — fewer financial barriers for patients should increase appropriate referrals and billed services for advanced imaging modalities.
Who Bears the Cost
- Private insurers and employers offering group plans — must absorb or manage higher imaging utilization and update plan designs and claims systems to eliminate cost-sharing for eligible members.
- State Medicaid programs and state budgets — mandatory coverage and the ban on benchmark carve-outs can increase Medicaid outlays, and states that need legislation will face implementation costs.
- Federal programs (Medicare, TRICARE, VA) and the federal budget — expanded no-cost-sharing benefits will shift additional utilization costs to federal programs and require administrative changes.
- Health systems and imaging providers — must manage increased demand for MRI/advanced imaging capacity, scheduling, and possible shifts in payer mix and reimbursement dynamics.
Key Issues
The Core Tension
The central dilemma is simple: expand access by eliminating cost-sharing and frequency limits for higher-risk and dense-breast populations to catch cancers earlier, versus the practical limits of health-system capacity and public budgets and the clinical trade-offs of more intensive imaging (false positives, downstream procedures). The bill privileges individual-level access and clinician discretion but leaves payers and programs to manage the population-level fiscal and operational consequences.
The bill deliberately relies on external clinical guidance (ACR Appropriateness Criteria, NCCN guidelines, and BI-RADS density categories) and clinician judgment to define who qualifies. That approach keeps the statute flexible and responsive to evolving evidence but creates variability: different clinicians and systems may interpret 'most recent applicable' guidance differently, producing inconsistent access across regions and payers.
Payers will need to codify operational definitions (e.g., which editions of guidance they accept, how to document clinician determination) to avoid disputes and audit risk.
Removing frequency limits removes a blunt administrative barrier but raises the prospect of substantial increases in imaging utilization and downstream follow-up (biopsies, visits). That may produce measurable fiscal impacts for Medicaid and federal programs and could exacerbate capacity constraints where MRI and molecular imaging access is limited today.
The bill does not set utilization-management guardrails (prior authorization, appropriateness review, coding edits) beyond tying eligibility to guidelines, so payers must balance access with stewardship without statutory detail. Finally, the interplay with USPSTF screening recommendations is significant: USPSTF grades often drive preventive coverage norms; this bill puts ACR/NCCN criteria front-and-center for this benefit, potentially creating divergence between guideline sets and complicating communications to patients and clinicians.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.